Pfizer and partner BioNTech reported favourable phase 3 data on COVID-19 vaccine BNT162b2, with an efficacy rate of over 90% and no major safety issues observed at an interim analysis. We are increasing the vaccine’s probability of approval to 90% from 60% in our model, supporting sales projections of EUR 13 billion in 2021.